Bazedoxifene
Also known as: Bazedoxifene acetate, TSE-424, Duavee, Viviant
Classification
Serm
Regulatory Status
FDA-approved as combination product component (DUAVEE); standalone US marketing not established
Sources
2
Review
n/a
Overview
Bazedoxifene is a selective estrogen receptor modulator with tissue-selective estrogen agonist/antagonist activity; in the US it is approved only in fixed combination with conjugated estrogens (DUAVEE).
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
Looked up as a third-generation SERM; US patients encounter it primarily as the bazedoxifene component of DUAVEE for labeled menopausal indications.
Interactions & cautions
Drug interactions
additional estrogens or estrogen agonists — DUAVEE labeling advises against taking additional estrogens. (high)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw